Lonza and Medarex, Inc. have signed a collaboration agreement under which Lonza will provide manufacturing services to support the development and commercialization of Medarex’s pipeline of therapeutic proteins and antibody drug conjugates (ADCs). As part of the agreement, Lonza may provide process development services for certain Medarex programs and may reserve manufacturing capacity for antibody and ADC programs at its biopharmaceutical facilities around the world. Further details were not disclosed.

“We are pleased to be working with such a successful mid-size biotech company to advance and strengthen their robust portfolio of innovative therapies,” said Dr. Stephan Kutzer, head of Lonza Biopharmaceuticals. “Supporting Medarex’s immediate and long-term needs with our expertise in mammalian cell culture and antibody drug conjugates is both exciting and rewarding.”

Medarex’s biologics portfolio is focused on treating oncology and immunology therapeutic indications with ten antibody programs in Phase III to Phase I development. Under the terms of the agreement, Lonza may be supporting a portion of the Medarex product pipeline.